FDA Grants Priority Review to Frontline Pembro to Treat Recurrent, Metastatic HNSCCFebruary 11th 2019
The FDA granted a priority review to the supplemental biologics license application for pembrolizumab (Keytruda) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal CancerJanuary 26th 2019
Pembrolizumab (Keytruda) was found to reduce the risk of death by 31% in patients with PD-L1–positive (combined positive score [CPS] ≥10) advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy, according to phase III findings of the KEYNOTE-181 trial.
Pembrolizumab/Trastuzumab Induction Highly Active in HER2+ Gastric, GEJ CancerJanuary 24th 2019
Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab (Keytruda), trastuzumab (Herceptin), and chemotherapy, a small clinical trial showed.
PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBCDecember 19th 2018
Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) in patients with metastatic triple-negative breast cancer (TNBC) or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells, according to a biomarker subgroup analysis of the phase III IMpassion130 study.1
Immuno-Oncology Clinic Develops Tools to Aid irAE Recognition and MonitoringDecember 14th 2018
Oncology nurses must not only be aware of the adverse events (AEs) of immunotherapy, but they must also educate their patients—and their other healthcare providers—to recognize them as well, according to Massey Nematollahi, MScN, RN, CNS, OCN, CON.
FDA Approves Frontline Atezolizumab Combo for Non-Small Cell Lung CancerDecember 7th 2018
The FDA has approved the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel (ABCP) for the frontline treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC). This indication excludes patients with EGFR/ALK aberrations.
Association of Community Cancer Centers Relaunches Immuno-Oncology Initiative to Meet Evolving Needs of Oncology CommunityNovember 30th 2018
ACCC worked closely with a team of multispecialty thought leaders via the IO Institute Working Groups to develop forward-thinking resources at the intersection of clinical science, care delivery, business, operations, and policy to support all facets of immunotherapy integration.
Assessing Barriers to Oral Oncolytic AdherenceNovember 30th 2018
Kathy Oubre, MS, Chief Operating Officer, Pontchartrain Cancer Center in Covington, Louisiana, shares some barriers to adherence to oral oncolytics that patients may face.
Pembrolizumab's Journey to the Frontline in NSCLCNovember 26th 2018
The PD-1 inhibitor pembrolizumab (Keytruda) has shown an overall survival advantage across 3 phase III clinical trials studying its use in patients with metastatic non–small cell lung cancer (NSCLC). These positive results led to a frontline indication as a single agent and in combination with chemotherapy for both patients with squamous and nonsquamous NSCLC.
Immunotherapy Pioneers Win Nobel Prize for Research on Checkpoint InhibitorsOctober 4th 2018
Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.
FDA Grants Priority Review to Elotuzumab Combination to Treat Multiple MyelomaAugust 23rd 2018
The FDA has granted a priority review to the immunostimulatory monoclonal antibody elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) to treat patients with relapsed/refractory multiple myeloma (MM) who have received 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.
Pediatric Guidelines for CAR T-Cell Therapy Help Nurses Recognize AEs EarlierAugust 23rd 2018
A year after the first CAR T-cell therapy was approved to treat pediatric patients with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), researchers have issued guidelines to help healthcare professionals recognize and treat the associated adverse events (AEs) from this treatment.
FDA Approves Nivolumab/Ipilimumab for Metastatic CRC SubgroupJuly 11th 2018
The FDA granted an accelerated approval to the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for use in adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
A Guide to Nursing Discharge of Patients Receiving CAR T-Cell TherapyJune 29th 2018
Standardized and focused education for patients receiving CAR T-cell therapy and their caregivers should be part of discharge procedures.
Liso-Cel Shows Promise in High-Risk Diffuse Large B-Cell LymphomaJune 7th 2018
A promising CD19-directed chimeric antigen (CAR) T-cell therapy, Lisocabtagene maraleucel (JCAR017; liso-cel), may result in durable remissions among patients with high-risk diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.